Global Cancer Diagnostics Market Development Status, Trends, Structure, Production Value, 2017-2024
Global Cancer Diagnostics Market is projected to reach USD 18.4 billion by 2024 from USD 7.6 billion in 2016, at a CAGR of 11.7% in the forecast period 2017 to 2024.
Cancer is defined as a malignant growth or tumor resulting from an uncontrolled division of cells. According to Centers for Disease Control and Prevention (CDC), cancer is the second leading cause of mortality, causing approximately 584,881 deaths worldwide in 2013. Early diagnosis is the key to prevent the rising number of cancer-related deaths. The global cancer diagnostics market is witnessing a rapid transformation owing to several technological advancements in diagnostic platforms such as next-generation sequencing, DNA microarrays, and polymerase chain reaction (PCR), among others. Moreover, the market has seen the advent of hybrid imaging instruments with enhanced accuracy, such as PET/CT and SPECT/CT. These advancements have augmented the growth of the cancer diagnostics market.
Get Free Report Sample @ https://databridgemarketresearch.com/request-a-sample/?dbmr=global-cancer-diagnostics-market
By Technology
• ELISA,
• ELFA,
• PCR,
• NGS,
• Immunohistochemistry,
• Microarray,
Imaging
• MRI,
• CT,
• PET,
• Ultrasound,
• Mammography
• Biopsy
Application
• Breast Cancer,
• Lung Cancer,
• Colorectal Cancer,
• Melanoma
Geography
• North America,
• Europe,
• APAC,
• South America,
• Rest of the World
Read Full TOC with Tables at @ https://databridgemarketresearch.com/toc/?dbmr=global-cancer-diagnostics-market
Market Segmentation: Cancer Diagnostics Market
The Cancer Diagnostics Market is segmented on the basis of technology and application.
The Global Cancer Diagnostics Market, by technology, is categorized into two main segments—platform based and instrument-based. Platform-based segment is further segmented into Polymerase Chain Reaction (PCR), In Situ Hybridization (ISH), Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), DNA Microarrays, Flow Cytometry and other technologies. Instrument-based segment is further segmented into Imaging (Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Positron Emission Tomography (PET), mammography, and ultrasound), and Biopsy.
The global cancer diagnostics market is segmented based on application into lung cancer, breast cancer, colorectal cancer, melanoma and other forms of cancer. Breast cancer diagnosis is expected to hold the largest share of this market in 2015, due to its high prevalence in North America also due to high expense of mammography instruments.
Competitive Landscape: Cancer Diagnostics Market
The global cancer diagnostics market is highly fragmented with various companies operating in local regions. The major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market.The global cancer diagnostics market report contains an in-depth profiling of the key market players, along with the recent developments (new product launches, partnerships, agreements, collaborations, and joint ventures) and strategies adopted by them to sustain and strengthen their position in the market.
Inquiry before Buying @ https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-cancer-diagnostics-market
Some of the major players operating in this Cancer Diagnostics Market
• Abbott Laboratories, Inc.,
• Thermo Fisher Scientific, Inc.,
• Illumina, Inc., Becton,
• Dickinson and Company,
• General Electric Company,
• QIAGEN N.V.,
• Agilent Technologies, Inc.,
• Hoffmann-La Roche Ltd.,
• Siemens Healthcare GmbH,
• Koninklijke Philips N.V.,
• C.R. Bard, Inc.,
• Hologic, Inc.
For more information about this report visit @ https://databridgemarketresearch.com/news/product-launch/global-cancer-diagnostics-market/
About Us:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: sopan.gedam@databridgemarketresearch.com
Cancer is defined as a malignant growth or tumor resulting from an uncontrolled division of cells. According to Centers for Disease Control and Prevention (CDC), cancer is the second leading cause of mortality, causing approximately 584,881 deaths worldwide in 2013. Early diagnosis is the key to prevent the rising number of cancer-related deaths. The global cancer diagnostics market is witnessing a rapid transformation owing to several technological advancements in diagnostic platforms such as next-generation sequencing, DNA microarrays, and polymerase chain reaction (PCR), among others. Moreover, the market has seen the advent of hybrid imaging instruments with enhanced accuracy, such as PET/CT and SPECT/CT. These advancements have augmented the growth of the cancer diagnostics market.
Get Free Report Sample @ https://databridgemarketresearch.com/request-a-sample/?dbmr=global-cancer-diagnostics-market
By Technology
• ELISA,
• ELFA,
• PCR,
• NGS,
• Immunohistochemistry,
• Microarray,
Imaging
• MRI,
• CT,
• PET,
• Ultrasound,
• Mammography
• Biopsy
Application
• Breast Cancer,
• Lung Cancer,
• Colorectal Cancer,
• Melanoma
Geography
• North America,
• Europe,
• APAC,
• South America,
• Rest of the World
Read Full TOC with Tables at @ https://databridgemarketresearch.com/toc/?dbmr=global-cancer-diagnostics-market
Market Segmentation: Cancer Diagnostics Market
The Cancer Diagnostics Market is segmented on the basis of technology and application.
The Global Cancer Diagnostics Market, by technology, is categorized into two main segments—platform based and instrument-based. Platform-based segment is further segmented into Polymerase Chain Reaction (PCR), In Situ Hybridization (ISH), Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), DNA Microarrays, Flow Cytometry and other technologies. Instrument-based segment is further segmented into Imaging (Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Positron Emission Tomography (PET), mammography, and ultrasound), and Biopsy.
The global cancer diagnostics market is segmented based on application into lung cancer, breast cancer, colorectal cancer, melanoma and other forms of cancer. Breast cancer diagnosis is expected to hold the largest share of this market in 2015, due to its high prevalence in North America also due to high expense of mammography instruments.
Competitive Landscape: Cancer Diagnostics Market
The global cancer diagnostics market is highly fragmented with various companies operating in local regions. The major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market.The global cancer diagnostics market report contains an in-depth profiling of the key market players, along with the recent developments (new product launches, partnerships, agreements, collaborations, and joint ventures) and strategies adopted by them to sustain and strengthen their position in the market.
Inquiry before Buying @ https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-cancer-diagnostics-market
Some of the major players operating in this Cancer Diagnostics Market
• Abbott Laboratories, Inc.,
• Thermo Fisher Scientific, Inc.,
• Illumina, Inc., Becton,
• Dickinson and Company,
• General Electric Company,
• QIAGEN N.V.,
• Agilent Technologies, Inc.,
• Hoffmann-La Roche Ltd.,
• Siemens Healthcare GmbH,
• Koninklijke Philips N.V.,
• C.R. Bard, Inc.,
• Hologic, Inc.
For more information about this report visit @ https://databridgemarketresearch.com/news/product-launch/global-cancer-diagnostics-market/
About Us:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: sopan.gedam@databridgemarketresearch.com